Targeting Th17 cells in immune diseases
- PMID: 25022899
- PMCID: PMC4123301
- DOI: 10.1038/cr.2014.92
Targeting Th17 cells in immune diseases
Abstract
Last decade has seen quick developments in the understanding of a new type of T lymphocytes, Th17 cells. This information is benefiting the understanding and treatment of a variety of inflammatory diseases, as suggested by a recent paper in Immunity.
Comment on
-
Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts.J Immunol. 2009 Mar 1;182(5):2565-8. doi: 10.4049/jimmunol.0803931. J Immunol. 2009. PMID: 19234148 Free PMC article.
-
Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2.Immunity. 2012 Jan 27;36(1):23-31. doi: 10.1016/j.immuni.2011.10.019. Epub 2012 Jan 12. Immunity. 2012. PMID: 22244845 Free PMC article.
-
A validated regulatory network for Th17 cell specification.Cell. 2012 Oct 12;151(2):289-303. doi: 10.1016/j.cell.2012.09.016. Epub 2012 Sep 25. Cell. 2012. PMID: 23021777 Free PMC article.
References
-
- Dong C. Nat Rev Immunol. 2008. pp. 337–348. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources